Crescita Therapeutics Inc. (TSX:CTX)
Canada · Delayed Price · Currency is CAD 0.7900
0.00 (0.00%)
Inactive · Last trade price on Jun 4, 2026
Crescita Therapeutics Ratios and Metrics
Market cap in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 15 | 9 | 11 | 10 | 13 | 14 | |
Market Cap Growth | 36.92% | -19.68% | 13.57% | -27.40% | -1.08% | -5.64% |
Enterprise Value | 8 | 1 | 4 | 1 | 4 | 4 |
Last Close Price | 0.79 | 0.48 | 0.58 | 0.49 | 0.66 | 0.65 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 15.65 | - |
PS Ratio | 0.63 | 0.42 | 0.57 | 0.56 | 0.57 | 0.81 |
PB Ratio | 1.02 | 0.57 | 0.70 | 0.52 | 0.64 | 0.66 |
P/TBV Ratio | 1.12 | 0.63 | 0.79 | 0.58 | 0.74 | 0.81 |
P/FCF Ratio | 22.01 | - | 17.71 | 5.04 | - | - |
P/OCF Ratio | 8.51 | 8.33 | 4.08 | 4.72 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.37 | 0.05 | 0.18 | 0.06 | 0.19 | 0.26 |
EV/EBITDA Ratio | 24.00 | 25.24 | - | - | 2.71 | - |
EV/EBIT Ratio | - | - | - | - | 8.26 | - |
EV/FCF Ratio | 12.72 | - | 5.75 | 0.56 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.17 | 0.02 | 0.05 | 0.07 | 0.08 | 0.14 |
Debt / EBITDA Ratio | 6.76 | 0.70 | - | - | 0.81 | - |
Debt / FCF Ratio | 3.74 | - | 1.33 | 0.65 | - | - |
Net Debt / Equity Ratio | -0.43 | -0.53 | -0.53 | -0.43 | -0.32 | -0.42 |
Net Debt / EBITDA Ratio | 95.52 | -187.41 | 3.71 | 9.49 | -4.15 | 17.83 |
Net Debt / FCF Ratio | -9.29 | 235.60 | -13.44 | -4.19 | 5.36 | 4.40 |
Asset Turnover | 1.06 | 1.00 | 0.84 | 0.66 | 0.82 | 0.60 |
Inventory Turnover | 2.38 | 2.28 | 2.08 | 1.22 | 2.06 | 1.72 |
Quick Ratio | 2.00 | 2.27 | 1.99 | 2.50 | 2.40 | 2.25 |
Current Ratio | 2.81 | 3.33 | 2.78 | 3.80 | 3.39 | 2.99 |
Return on Equity (ROE) | -2.19% | -0.59% | -15.87% | -9.95% | 4.14% | -5.30% |
Return on Assets (ROA) | -3.31% | -3.03% | -8.67% | -4.61% | 1.15% | -3.35% |
Return on Invested Capital (ROIC) | -14.99% | -13.89% | -35.57% | -15.59% | 4.01% | -14.96% |
Return on Capital Employed (ROCE) | -7.00% | -6.50% | -19.80% | -9.90% | 2.40% | -6.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -2.18% | -1.03% | -24.72% | -20.28% | 6.39% | -8.10% |
FCF Yield | 4.54% | -0.39% | 5.65% | 19.84% | -9.26% | -14.25% |
Buyback Yield / Dilution | 2.43% | 2.61% | 4.44% | 3.55% | -1.18% | 1.02% |